Cargando…
SAT-351 CYP11B1 Is a Highly Accurate Marker of Malignancy in Functioning Adrenocortical Tumors
Autonomous steroid secretion is a common feature of adrenocortical carcinomas (ACCs). However, steroid overproduction in ACC is not always clinically evident owing to inefficient steroidogenesis with increased release of steroid precursors in result of an incomplete pattern of steroidogenic enzyme e...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Endocrine Society
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6551966/ http://dx.doi.org/10.1210/js.2019-SAT-351 |
_version_ | 1783424496834707456 |
---|---|
author | Pereira, Sofia Costa, Madalena Gomez-Sanchez, Celso Pignatelli, Duarte |
author_facet | Pereira, Sofia Costa, Madalena Gomez-Sanchez, Celso Pignatelli, Duarte |
author_sort | Pereira, Sofia |
collection | PubMed |
description | Autonomous steroid secretion is a common feature of adrenocortical carcinomas (ACCs). However, steroid overproduction in ACC is not always clinically evident owing to inefficient steroidogenesis with increased release of steroid precursors in result of an incomplete pattern of steroidogenic enzyme expression Immunohistochemical expression of protein involved in steroidogenesis, namely steroidogenic acute regulatory protein (StAR), 11β-hydroxylase (CYP11B1), aldosterone synthase (CYP11B2) and 17α-hydroxylase, were analyzed in ACCs (n=15), adenomas presenting with Cushing Syndrome (CUSH) (n=15) and clinically non-functioning adenomas (nACA) (n=15). The percentage of the stained area for each protein was analyzed using the ImageJ software for computerized morphometric quantification. CYP11B2 was found to be poorly expressed in all the tumors analyzed. CYP11B1, StAR and 17α-hydroxylase expression was significantly lower in ACCs when compared to CUSH, while CYP11B1 showed to be the most discriminative steroidogenic enzyme to distinguish ACC from CUSH with a sensitivity of 100% and specificity of 92%. CYP11B1 and CYP11B2 dual negativity presented a specificity of 100% for the differential diagnosis between ACC and CUSH. In conclusion, ACC depicted an incomplete pattern of steroidogenic protein expression, with decreased StAR, CYP11B1 and 17 α-hydroxylase, which could explain the predominant secretion of steroid precursors. Moreover, CYP11B1 is a highly accurate marker to differentiate ACC from CUSH. Thus, CYP1B1 negativity has the potential of being useful as a diagnostic tool to identify malignancy in steroid secreting adrenocortical tumors. Funding: This work was funded by FCT (PTDC/MEC-ONC/31384/2017). |
format | Online Article Text |
id | pubmed-6551966 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Endocrine Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-65519662019-06-13 SAT-351 CYP11B1 Is a Highly Accurate Marker of Malignancy in Functioning Adrenocortical Tumors Pereira, Sofia Costa, Madalena Gomez-Sanchez, Celso Pignatelli, Duarte J Endocr Soc Adrenal Autonomous steroid secretion is a common feature of adrenocortical carcinomas (ACCs). However, steroid overproduction in ACC is not always clinically evident owing to inefficient steroidogenesis with increased release of steroid precursors in result of an incomplete pattern of steroidogenic enzyme expression Immunohistochemical expression of protein involved in steroidogenesis, namely steroidogenic acute regulatory protein (StAR), 11β-hydroxylase (CYP11B1), aldosterone synthase (CYP11B2) and 17α-hydroxylase, were analyzed in ACCs (n=15), adenomas presenting with Cushing Syndrome (CUSH) (n=15) and clinically non-functioning adenomas (nACA) (n=15). The percentage of the stained area for each protein was analyzed using the ImageJ software for computerized morphometric quantification. CYP11B2 was found to be poorly expressed in all the tumors analyzed. CYP11B1, StAR and 17α-hydroxylase expression was significantly lower in ACCs when compared to CUSH, while CYP11B1 showed to be the most discriminative steroidogenic enzyme to distinguish ACC from CUSH with a sensitivity of 100% and specificity of 92%. CYP11B1 and CYP11B2 dual negativity presented a specificity of 100% for the differential diagnosis between ACC and CUSH. In conclusion, ACC depicted an incomplete pattern of steroidogenic protein expression, with decreased StAR, CYP11B1 and 17 α-hydroxylase, which could explain the predominant secretion of steroid precursors. Moreover, CYP11B1 is a highly accurate marker to differentiate ACC from CUSH. Thus, CYP1B1 negativity has the potential of being useful as a diagnostic tool to identify malignancy in steroid secreting adrenocortical tumors. Funding: This work was funded by FCT (PTDC/MEC-ONC/31384/2017). Endocrine Society 2019-04-30 /pmc/articles/PMC6551966/ http://dx.doi.org/10.1210/js.2019-SAT-351 Text en Copyright © 2019 Endocrine Society https://creativecommons.org/licenses/by-nc-nd/4.0/ This article has been published under the terms of the Creative Commons Attribution Non-Commercial, No-Derivatives License (CC BY-NC-ND; https://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Adrenal Pereira, Sofia Costa, Madalena Gomez-Sanchez, Celso Pignatelli, Duarte SAT-351 CYP11B1 Is a Highly Accurate Marker of Malignancy in Functioning Adrenocortical Tumors |
title | SAT-351 CYP11B1 Is a Highly Accurate Marker of Malignancy in Functioning Adrenocortical Tumors |
title_full | SAT-351 CYP11B1 Is a Highly Accurate Marker of Malignancy in Functioning Adrenocortical Tumors |
title_fullStr | SAT-351 CYP11B1 Is a Highly Accurate Marker of Malignancy in Functioning Adrenocortical Tumors |
title_full_unstemmed | SAT-351 CYP11B1 Is a Highly Accurate Marker of Malignancy in Functioning Adrenocortical Tumors |
title_short | SAT-351 CYP11B1 Is a Highly Accurate Marker of Malignancy in Functioning Adrenocortical Tumors |
title_sort | sat-351 cyp11b1 is a highly accurate marker of malignancy in functioning adrenocortical tumors |
topic | Adrenal |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6551966/ http://dx.doi.org/10.1210/js.2019-SAT-351 |
work_keys_str_mv | AT pereirasofia sat351cyp11b1isahighlyaccuratemarkerofmalignancyinfunctioningadrenocorticaltumors AT costamadalena sat351cyp11b1isahighlyaccuratemarkerofmalignancyinfunctioningadrenocorticaltumors AT gomezsanchezcelso sat351cyp11b1isahighlyaccuratemarkerofmalignancyinfunctioningadrenocorticaltumors AT pignatelliduarte sat351cyp11b1isahighlyaccuratemarkerofmalignancyinfunctioningadrenocorticaltumors |